{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:05Z","timestamp":1786979945098,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2015CB755505"],"award-info":[{"award-number":["2015CB755505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81372685 and 81872059"],"award-info":[{"award-number":["81372685 and 81872059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["202002030114"],"award-info":[{"award-number":["202002030114"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515010702"],"award-info":[{"award-number":["2019A1515010702"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2016A030313309"],"award-info":[{"award-number":["2016A030313309"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81572479 and 81772677"],"award-info":[{"award-number":["81572479 and 81772677"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00280-020-04169-y","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T11:05:41Z","timestamp":1603105541000},"page":"773-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Combination of levetiracetam and IFN-\u03b1 increased temozolomide efficacy in MGMT-positive glioma"],"prefix":"10.1007","volume":"86","author":[{"given":"Xiang-Rong","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Cheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-7237","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-5771","authenticated-orcid":false,"given":"Zhong-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"1","key":"4169_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000163610","volume":"59","author":"LM Neckers","year":"1991","unstructured":"Neckers LM (1991) Regulation of transferrin receptor expression and control of cell growth. Pathobiology 59(1):11\u201318. https:\/\/doi.org\/10.1159\/000163610","journal-title":"Pathobiology"},{"key":"4169_CR2","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","DOI":"10.1056\/NEJMoa043330"},{"key":"4169_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2012.00098","volume":"2","author":"M Nakada","year":"2012","unstructured":"Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J (2012) The strategy for enhancing temozolomide against malignant glioma. Front Oncol 2:98. https:\/\/doi.org\/10.3389\/fonc.2012.00098","journal-title":"Front Oncol"},{"key":"4169_CR4","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1038\/cddis.2013.388","volume":"4","author":"CH Fan","year":"2013","unstructured":"Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G (2013) O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis 4:e876. https:\/\/doi.org\/10.1038\/cddis.2013.388","journal-title":"Cell Death Dis"},{"issue":"25","key":"4169_CR5","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","volume":"26","author":"ME Hegi","year":"2008","unstructured":"Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189\u20134199. https:\/\/doi.org\/10.1200\/JCO.2007.11.5964","journal-title":"J Clin Oncol"},{"issue":"12","key":"4169_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1055\/s-0034-1385475","volume":"82","author":"W Froscher","year":"2014","unstructured":"Froscher W, Kirschstein T, Rosche J (2014) Anticonvulsant therapy for brain tumour-related epilepsy. Fortschr Neurol Psychiatr 82(12):678\u2013690. https:\/\/doi.org\/10.1055\/s-0034-1385475","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"8","key":"4169_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jocn.2015.01.025","volume":"22","author":"Y Yuan","year":"2015","unstructured":"Yuan Y, Peizhi Z, Maling G, Wu L, Yunhe M, Xiang W, Qing M, Yanhui L, Ruofei L, Jiewen L (2015) The efficacy of levetiracetam for patients with supratentorial brain tumors. J Clin Neurosci 22(8):1227\u20131231. https:\/\/doi.org\/10.1016\/j.jocn.2015.01.025","journal-title":"J Clin Neurosci"},{"issue":"17","key":"4169_CR8","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/cncr.29439","volume":"121","author":"YH Kim","year":"2015","unstructured":"Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY (2015) Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 121(17):2926\u20132932. https:\/\/doi.org\/10.1002\/cncr.29439","journal-title":"Cancer"},{"issue":"9","key":"4169_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/neuonc\/noq044","volume":"12","author":"GC Bobustuc","year":"2010","unstructured":"Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12(9):917\u2013927. https:\/\/doi.org\/10.1093\/neuonc\/noq044","journal-title":"Neuro Oncol"},{"key":"4169_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12935-018-0626-8","volume":"18","author":"BM Scicchitano","year":"2018","unstructured":"Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica G (2018) Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int 18:136. https:\/\/doi.org\/10.1186\/s12935-018-0626-8","journal-title":"Cancer Cell Int"},{"issue":"6","key":"4169_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1179\/1973947813y.0000000102","volume":"25","author":"SA Coker","year":"2013","unstructured":"Coker SA, Dandamudi UB, Beelen AP, Crosby NA, Fisher JL, Obrocea M, Ernstoff MS, Lewis LD (2013) A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. J Chemother 25(6):362\u2013368. https:\/\/doi.org\/10.1179\/1973947813y.0000000102","journal-title":"J Chemother"},{"issue":"5","key":"4169_CR12","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3892\/or.2015.4232","volume":"34","author":"D Shen","year":"2015","unstructured":"Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, Chen YS, Chen FR, Wang J, Panasci L, Chen ZP (2015) Interferon-alpha\/beta enhances temozolomide activity against MGMT-positive glioma stem-like cells. Oncol Rep 34(5):2715\u20132721. https:\/\/doi.org\/10.3892\/or.2015.4232","journal-title":"Oncol Rep"},{"issue":"4","key":"4169_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00280-007-0520-x","volume":"61","author":"A Natsume","year":"2008","unstructured":"Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J (2008) A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61(4):653\u2013659. https:\/\/doi.org\/10.1007\/s00280-007-0520-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4169_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/cbr.1995.10.265","volume":"10","author":"RO Dillman","year":"1995","unstructured":"Dillman RO, Wiemann M, Oldham RK, Soori G, Bury M, Hafer R, Church C, DePriest C (1995) Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother 10(4):265\u2013271. https:\/\/doi.org\/10.1089\/cbr.1995.10.265","journal-title":"Cancer Biother"},{"issue":"3","key":"4169_CR15","first-page":"217","volume":"16","author":"QW Wu","year":"2017","unstructured":"Wu QW, Zhang ZP, Wang J, Chen FR, Zhao YY, Qu Y, Chen ZP (2017) In vitro study of antitumor effect of levetiracetam combined with temozolomide in glioma cell lines. Chin J Neurosurg Dis Res 16(3):217\u2013220","journal-title":"Chin J Neurosurg Dis Res"},{"issue":"8","key":"4169_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/neuonc\/nox016","volume":"19","author":"X Mei","year":"2017","unstructured":"Mei X, Chen YS, Chen FR, Xi SY, Chen ZP (2017) Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol 19(8):1109\u20131118. https:\/\/doi.org\/10.1093\/neuonc\/nox016","journal-title":"Neuro Oncol"},{"issue":"12","key":"4169_CR17","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1158\/0008-5472.CAN-10-3498","volume":"71","author":"WP Roos","year":"2011","unstructured":"Roos WP, Jost E, Belohlavek C, Nagel G, Fritz G, Kaina B (2011) Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid. Cancer Res 71(12):4150\u20134160. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3498","journal-title":"Cancer Res"},{"issue":"3","key":"4169_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","journal-title":"Genes Dis"},{"issue":"8","key":"4169_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/15384047.2019.1599662","volume":"20","author":"A Arora","year":"2019","unstructured":"Arora A, Somasundaram K (2019) Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther 20(8):1083\u20131090. https:\/\/doi.org\/10.1080\/15384047.2019.1599662","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"4169_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/glioma.glioma_26_19","volume":"2","author":"CM Xu","year":"2019","unstructured":"Xu CM, Zhao YD, Wu CY, Li L (2019) Repurposing drugs for the treatment of glioma. Glioma 2(2):159\u2013164. https:\/\/doi.org\/10.4103\/glioma.glioma_26_19","journal-title":"Glioma"},{"key":"4169_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09410-0","author":"M Romoli","year":"2019","unstructured":"Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Nardi Cesarini E, Verzina A, Calvello C, Loreti E, Sidoni A, Giovenali P, Calabresi P, Costa C (2019) Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. J Neurol. https:\/\/doi.org\/10.1007\/s00415-019-09410-0","journal-title":"J Neurol"},{"issue":"1","key":"4169_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-010-0460-x","volume":"104","author":"M Maschio","year":"2011","unstructured":"Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Muti P (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104(1):205\u2013214. https:\/\/doi.org\/10.1007\/s11060-010-0460-x","journal-title":"J Neurooncol"},{"issue":"2","key":"4169_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11060-017-2660-0","volume":"136","author":"AF Cardona","year":"2018","unstructured":"Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patino A, Arrieta O, Hakim EJ, Hakim F, Mejia JA, Useche N, Bermudez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortiz LD, Franco S, Ortiz C, Gil-Gil M, Balana C, Zatarain-Barron ZL (2018) Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol 136(2):363\u2013371. https:\/\/doi.org\/10.1007\/s11060-017-2660-0","journal-title":"J Neurooncol"},{"issue":"2","key":"4169_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbrc.2017.07.098","volume":"491","author":"Z Du","year":"2017","unstructured":"Du Z, Cai C, Sims M, Boop FA, Davidoff AM, Pfeffer LM (2017) The effects of type I interferon on glioblastoma cancer stem cells. Biochem Biophys Res Commun 491(2):343\u2013348. https:\/\/doi.org\/10.1016\/j.bbrc.2017.07.098","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"4169_CR25","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-05-0036","volume":"65","author":"A Natsume","year":"2005","unstructured":"Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65(17):7573\u20137579. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0036","journal-title":"Cancer Res"},{"issue":"4","key":"4169_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","volume":"14","author":"M De Palma","year":"2008","unstructured":"De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, Falini A, Guidotti LG, Galli R, Naldini L (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4):299\u2013311. https:\/\/doi.org\/10.1016\/j.ccr.2008.09.004","journal-title":"Cancer Cell"},{"issue":"4","key":"4169_CR27","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.3892\/ol.2018.7894","volume":"15","author":"F Shen","year":"2018","unstructured":"Shen F, Guo Q, Hu Q, Zeng A, Wu W, Yan W, You Y (2018) RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis. Oncol Lett 15(4):4404\u20134410. https:\/\/doi.org\/10.3892\/ol.2018.7894","journal-title":"Oncol Lett"},{"issue":"2","key":"4169_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02688697.2018.1540764","volume":"33","author":"I Kina","year":"2019","unstructured":"Kina I, Sultuybek GK, Soydas T, Yenmis G, Biceroglu H, Dirican A, Uzan M, Ulutin T (2019) Variations in Toll-like receptor and nuclear factor-kappa B genes and the risk of glioma. Br J Neurosurg 33(2):165\u2013170. https:\/\/doi.org\/10.1080\/02688697.2018.1540764","journal-title":"Br J Neurosurg"},{"issue":"8","key":"4169_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/09513590.2015.1032931","volume":"31","author":"L Akman","year":"2015","unstructured":"Akman L, Erbas O, Akdemir A, Yavasoglu A, Taskiran D, Kazandi M (2015) Levetiracetam ameliorates ovarian function in streptozotocin-induced diabetic rats. Gynecol Endocrinol 31(8):657\u2013662. https:\/\/doi.org\/10.3109\/09513590.2015.1032931","journal-title":"Gynecol Endocrinol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04169-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04169-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04169-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:44:48Z","timestamp":1634607888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04169-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04169-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal experiments were approved by the institutional ethics committee of Sun Yat-sen University Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}